• Faron Pharmaceuticals published its H1 2026 half-year report webcast transcript, featuring the Chief Executive Officer, the Chief Financial Officer, and investors.
• Management highlighted Phase I/II frontline high-risk MDS results for bexmarilimab plus azacitidine, citing a 45% complete remission rate.
• BEXERA Phase IIb: regulatory submissions filed in the US, Europe, UK; enrollment expected to finish around early August 2027; readout targeted November 2027.
• Go/no-go hinges on the complete remission endpoint; a 10% CR improvement versus azacitidine alone flagged as the minimum “go” threshold.
• Rights issue raised gross EUR 40 million, net EUR 32.8 million; June-end cash EUR 32 million; operating loss EUR 11.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.